News

October 23, 2018: Silk Technologies is excited to announce that the company has been selected to present at the 10th annual OIS@AAO conference in Chicago, IL on Thursday, October 25, 2018.  Silk Technologies’ CEO, Dr. Brian Lawrence, will be presenting pre-clinical and clinical development updates on their biologic drug candidate SDP-4 for the treatment of Dry Eye Disease.


April 2, 2018: SilkTech is planning to be attend the American Academy of Ophthalmology Conference (AAO 2018) in Chicago in October this year.


November 29, 2017: Silk Tech CEO Brian Lawrence, PhD interviewed by MergerMarket to discuss recent Skyview Capital Funding


November 20, 2017: Treatment with solubilized Silk-Derived Protein (SDP) enhances rabbit corneal epithelial wound healing published in PLOS Journal


November 8, 2017: Skyview Ventures has committed $11.2 Million to support development of SDP-4 through Phase-2 proof of concept studies. Skyview Capital Makes Significant Investment in Silk Technologies


November 6, 2017: SilkTech is excited to be attending the American Academy of Ophthalmology Conference (AAO 2017) in New Orleans this year.


November 1, 2017: Startup raises $11M to turn silkworm cocoons into eye drops.  A biotech startup that aims to turn silkworm cocoons into a treatment for dry-eye disease has raised $11.2 million in financing.Plymouth-based Silk Technologies Ltd. will put the capital toward early testing of its product, an eye drop made from silk fibers, said founder and CEO Brian Lawrence. Skyview Capital, a Los Angeles-based investment firm, was the sole investor in the round. Read More


March, 2017: “Silk-Derived Protein Enhances Corneal Epithelial Migration, Adhesion, and Proliferation” paper released